Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
11(61.1%)
Phase 2
3(16.7%)
Phase 1
2(11.1%)
Early Phase 1
1(5.6%)
Phase 4
1(5.6%)
18Total
N/A(11)
Phase 2(3)
Phase 1(2)
Early Phase 1(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT05458323Not ApplicableRecruiting

Cognitive Level Enhancement Through Vision Exams and Refraction

Role: collaborator

NCT05510687Not ApplicableActive Not Recruiting

Transforming Households With Refraction and Innovative Financial Technology

Role: collaborator

NCT05466955Not ApplicableRecruiting

Slashing Two-wheeled Accidents by Leveraging Eyecare

Role: collaborator

NCT06613919Phase 4Completed

Six-months Versus Nine-months ATT for Ocular TB

Role: lead

NCT05538182Not ApplicableCompleted

Zimbabwe Eyecare And Learning(ZEAL):Formative Research on Hyperopia and Educational Outcomes in Primary School Children

Role: collaborator

NCT03548805Not ApplicableCompleted

Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma

Role: lead

NCT03541551Not ApplicableCompleted

Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy

Role: lead

NCT04618510Not ApplicableUnknown

SEED-LVPEI Myopia Study

Role: lead

NCT04932629Early Phase 1Unknown

To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".

Role: lead

NCT04843839Phase 2Unknown

CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

Role: lead

NCT03295292Phase 1Unknown

Limbus-derived Stem Cells for Prevention of Postoperative Corneal Haze

Role: lead

NCT02424006Not ApplicableCompleted

Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea in Patients Requiring Anterior Lamellar Keratoplasty

Role: lead

NCT03571659Completed

Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema

Role: lead

NCT02948023Phase 1Unknown

Stem Cells Therapy for Corneal Blindness

Role: lead

NCT03230058Phase 2Unknown

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis

Role: lead

NCT00386958Phase 2Completed

A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

Role: collaborator

NCT02798848Not ApplicableUnknown

CREATE - Children Reading With Electronic Assistance To Educate

Role: collaborator

NCT01218230Not ApplicableWithdrawn

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

Role: lead

NCT01023113Not ApplicableUnknown

To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation

Role: lead

All 19 trials loaded